The Meso Scale Discovery Assay is non-radioactive and it uses electrochemiluminescence, unlike the colorimetric or chemiluminescent reaction in ELISA. MSD ECL Assays are superior to traditional ELISA in many aspects, even as the various viable assay versions are quite like different types of ELISA. MSD Quick Plex 120 instrument applies the robust and sensitive electrochemiluminescence technology to quantitate single and multiple target analyte. MSD Assays enable accurate determination of analytes in complex biological matrices with improved throughput in a cost-effective and timely manner.
Msd mesoscale scientists have developed an ultra-sensitive ELISA based assay with chemiluminescence technology that is suitable for immune-based assays. The tests are significantly more sensitive than standard ELISA procedures and are compatible with a broad range of sample types, including whole blood and serum, as well as tissue homogenates.
We have developed a new immunogenicity assay system, which has been validated by our own in-house proprietary methods. The system utilizes electrochemiluminescence (ECL) to detect specific antibodies against the invitrogen reagents used for the standard HITI ELISA test. The ECL spectrum is able to detect antibodies against many external antigens, more sensitive than colorimetric methods and with much higher sensitivity than chemiluminescence.
If you are in the research and development industry, then you must be aware of the importance of an efficient and cost-effective bioanalysis platform. It is helpful for industry to cut down on their overall costs and to develop new products at lower prices. Most scientists today believe that high-throughput screening techniques such as MALDI-TOF allows them to reach new milestones in drug discovery. However, there are also other methods available as well that help researchers test predictors related to therapeutics development more efficiently.
What is immunogenicity: Immunogenicity testing plays a crucial role in measuring the immune response elicited by large molecule drugs during biotherapeutics R&D. Given its defense mechanism, the human immune system marks large molecules as foreign invaders and mounts a subsequent reaction. Typically, this happens through the production of antibodies to remove or destroy the external elements. During the immune response, the large molecules can create even larger macromolecules that further change the immunogenicity profile of the underlying drug. In other words, the immune response triggered by the therapeutic compound or its delivery vehicle can impact the efficacy and safety of the drug. Thus, immunogenicity testing is an essential step in biopharmaceutical development.
Immunogenicity testing plays a crucial role in measuring the immune response elicited by large molecule drugs during biotherapeutics R&D. Given its defense mechanism, the human immune system marks large molecules as foreign invaders and mounts a subsequent reaction. Typically, this happens through the production of antibodies to remove or destroy the external elements. During the immune response, the large molecules can create even larger macromolecules that further change the immunogenicity profile of the underlying drug. In other words, the immune response triggered by the therapeutic compound or its delivery vehicle can impact the efficacy and safety of the drug.
Immunogenicity testing plays a crucial role in measuring the immune response elicited by large molecule drugs during biotherapeutics R&D. Given its defense mechanism, the human immune system marks large molecules as foreign invaders and mounts a subsequent reaction. Typically, this happens through the production of antibodies to remove or destroy the external elements. During the immune response, the large molecules can create even larger macromolecules that further change the immunogenicity profile of the underlying drug.